Markets

Teva Settles Foreign Bribery Charges with U.S. Government

Pharmaceutical giant Teva Pharmaceuticals Industries Ltd.TEVA announced that it has completed negotiations with the U.S. government over violations of the Foreign Corrupt Practices Act (FCPA).

A look at Teva's year-to-date share price movement shows that the company has underperformed the Zacks classified Generic Drugs industry. Specifically, the stock lost 43.7% during this period, compared with the 39.1% drop for the industry.

Coming back to the latest news, the company has agreed to pay more than $519 million to settle civil and criminal charges of having violated the FCPA bribing government officials of Russia, Ukraine, and Mexico.

We note that the Securities and Exchange Commission (SEC) alleged that Teva had obtained illegal profits worth more than $214 million by carrying out influential payments to government officials in these regions in order to increase its market share, and obtain regulatory approvals, as well as favorable drug purchase and prescription decisions.

As per the settlement, Teva will pay more than $236 million in disgorgement and interest to the SEC. In addition, a penalty of $283 million has to be paid to the U.S. Justice of Department (DOJ) as part of a deferred prosecution agreement. Moreover, the company must retain an independent corporate monitor for at least three years.

We remind investors that in 2012, Teva started a voluntary and comprehensive investigation into its global operations to address government's specific requests for documents and information. The company had engaged an independent counsel to assist in the investigation, and conducted a global corruption risk assessment and a multi-country survey.

Going forward, we expect investors to focus on further updates from the company related to the settlement.

TEVA PHARM ADR Price and Consensus

TEVA PHARM ADR Price and Consensus | TEVA PHARM ADR Quote

Teva currently carries a Zacks Rank #4 (Sell).

Key Picks in the Sector

Some better-ranked stocks in the health care sector include Vanda Pharmaceuticals Inc. VNDA , Cambrex Corp. CBM and Heska Corp. HSKA . Each of them sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Both Vanda and Cambrex posted a positive earnings surprise thrice in the four trailing quarters with an average beat of 56.65% and 19.78%, respectively. Heska, on the other hand, posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CAMBREX CORP (CBM): Free Stock Analysis Report

HESKA CORP (HSKA): Free Stock Analysis Report

VANDA PHARMACT (VNDA): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VNDA HSKA CBM TEVA

Other Topics

Stocks

Latest Markets Videos